Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Kymera Therapeutics's enterprise value was $10.47B on Nov 11, 2026, against $4.36B a year earlier. Over the last 5 years it ranged from $278.83M to $10.47B, with a median of $1.74B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $10.47B | +106.3% |
| 2025 | Dec 31, 2025 | $5.08B | +147.0% |
| 2024 | Dec 31, 2024 | $2.05B | +95.0% |
| 2023 | Dec 29, 2023 | $1.05B | +19.1% |
| 2022 | Dec 30, 2022 | $884.69M | -67.4% |
| 2021 | Dec 31, 2021 | $2.72B | +10.4% |
| 2020 | Dec 31, 2020 | $2.46B | – |
See a number that looks wrong?